ALK and non-small cell lung carcinoma: This contrasts starkly with the rapid approval of crizotinib for anaplastic lymphoma kinase gene–rearranged non-small cell lung cancer (NSCLC); crizotinib was approved approximately 2 years after its anticancer activity was initially observed [11].